摘要
目的探讨瑞舒伐他汀联合曲美他嗪对冠状动脉粥样硬化性心脏病(冠心病)患者的治疗效果。方法80例冠心病患者,以随机数字表法分为曲美他嗪治疗组与瑞舒伐他汀联合曲美他嗪治疗组,各40例。曲美他嗪治疗组选择曲美他嗪治疗,瑞舒伐他汀联合曲美他嗪治疗组选择曲美他嗪联合瑞舒伐他汀治疗。比较两组疗效;心功能改善2级时间、住院总时间;用药前后低密度脂蛋白胆固醇、总胆固醇、三酰甘油、高密度脂蛋白胆固醇、6 min步行距离以及左心室射血分数;药物不良反应。结果瑞舒伐他汀联合曲美他嗪治疗组治疗总有效率为100.00%,高于曲美他嗪治疗组的75.00%,差异有统计学意义(P<0.05)。治疗后,瑞舒伐他汀联合曲美他嗪治疗组低密度脂蛋白胆固醇(2.21±0.51)mmol/L、总胆固醇(5.01±0.51)mmol/L、三酰甘油(1.24±0.22)mmol/L均低于曲美他嗪治疗组的(3.52±0.67)、(5.56±0.78)、(1.78±0.43)mmol/L,高密度脂蛋白胆固醇(1.52±0.21)mmol/L、左心室射血分数(53.19±8.31)%均高于曲美他嗪治疗组的(1.24±0.22)mmol/L、(45.44±8.21)%,6 min步行距离(380.13±20.01)m长于曲美他嗪治疗组的(320.24±20.56)m,差异有统计学意义(P<0.05)。瑞舒伐他汀联合曲美他嗪治疗组心功能改善2级时间(11.25±1.31)d、住院总时间(13.55±0.55)d均短于曲美他嗪治疗组的(15.45±1.65)、(16.56±0.91)d,差异有统计学意义(P<0.05)。瑞舒伐他汀联合曲美他嗪治疗组药物不良反应发生率为7.50%,与曲美他嗪治疗组的10.00%比较,差异无统计学意义(P>0.05)。结论曲美他嗪联合瑞舒伐他汀治疗冠心病的疗效肯定,可有效调节血脂异常代谢,改善心功能以及增强患者的机体耐力,且可缩短住院时间,未增加不良反应。
Objective To discuss the therapeutic effect of rosuvastatin combined with trimetazidine on patients with coronary heart disease.Methods A total of 80 patients with coronary heart disease were divided into trimetazidine group and rosuvastatin combined with trimetazidine group by random number table method,with 40 cases in each group.Trimetazidine group was treated by trimetazidine,and rosuvastatin combined with trimetazidine group was treated by rosuvastatin combined with trimetazidine.The efficacy,time for cardiac function improvement 2 grades,total hospitalization time;low density lipoprotein cholesterol,total cholesterol,triacylglycerol and high density lipoprotein cholesterol before and after treatment,6 min walking distance and left ventricular ejection fraction,adverse drug reactions were compared between the two groups.Results The total effective rate of treatment was 100.00%in rosuvastatin combined with trimetazidine group,which was higher than 75.00%in trimetazidine group,and the difference was statistically significant(P<0.05).After treatment,the low density lipoprotein cholesterol and total cholesterol(2.21±0.51)mmol/L,total cholesterol(5.01±0.51)mmol/L and triacylglycerol(1.24±0.22)mmol/L in rosuvastatin combined with trimetazidine group were lower than(3.52±0.67),(5.56±0.78)and(1.78±0.43)mmol/L in trimetazidine group.The high density lipoprotein cholesterol(1.52±0.21)mmol/L and left ventricular ejection fraction(53.19±8.31)%in rosuvastatin combined with trimetazidine group were higher than(1.24±0.22)mmol/L and(45.44±8.21)%in trimetazidine group,and 6 min walking distance(380.13±20.01)m was longer than(320.24±20.56)m in trimetazidine group.Their difference was statistically significant(P<0.05).Time for cardiac function improvement 2 grades(11.25±1.31)d and total hospitalization time(13.55±0.55)d in rosuvastatin combined with trimetazidine group were shorter than(15.45±1.65)and(16.56±0.91)d in trimetazidine group,and their difference was statistically significant(P<0.05).The incidence of side effect of drugs was 7.50%in rosuvastatin combined with trimetazidine group,and it had no statistically significant difference compared with 10.00%in trimetazidine group(P>0.05).Conclusion Trimetazidine combined with rosuvastatin shows affirmative efficacy on patients with coronary heart disease,and it can effectively regulate the metabolism of dyslipidemia,improve the heart function and enhance the body endurance of patients,as well as shortening the hospitalization time without increasing side effects.
作者
蒋丽
JIANG Li(Dalian Central Hospital,Dalian 116033,China)
出处
《中国现代药物应用》
2020年第3期10-12,共3页
Chinese Journal of Modern Drug Application
